Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants (the SToP-BPD study); a multicenter randomized placebo controlled trial by Onland, W. et al.
STUDY PROTOCOL Open Access
Systemic Hydrocortisone To Prevent
Bronchopulmonary Dysplasia in preterm infants
(the SToP-BPD study); a multicenter randomized
placebo controlled trial
Wes Onland1, Martin Offringa1,2, Filip Cools3, Anne P De Jaegere1, Karin Rademaker4, Henry Blom5, Eric Cavatorta6,
Anne Debeer7, Peter H Dijk8, Arno F van Heijst9, Boris W Kramer10, Andre A Kroon11, Thilo Mohns12,
Henrica L van Straaten13, Arjan B te Pas14, Claire Theyskens15, Mirjam M van Weissenbruch16 and
Anton H van Kaam1*
Abstract
Background: Randomized controlled trials have shown that treatment of chronically ventilated preterm infants
after the first week of life with dexamethasone reduces the incidence of the combined outcome death or
bronchopulmonary dysplasia (BPD). However, there are concerns that dexamethasone may increase the risk of
adverse neurodevelopmental outcome. Hydrocortisone has been suggested as an alternative therapy. So far no
randomized controlled trial has investigated its efficacy when administered after the first week of life to ventilated
preterm infants.
Methods/Design: The SToP-BPD trial is a randomized double blind placebo controlled multicenter study including
400 very low birth weight infants (gestational age < 30 weeks and/or birth weight < 1250 grams), who are
ventilator dependent at a postnatal age of 7 - 14 days. Hydrocortisone (cumulative dose 72.5 mg/kg) or placebo is
administered during a 22 day tapering schedule. Primary outcome measure is the combined outcome mortality or
BPD at 36 weeks postmenstrual age. Secondary outcomes are short term effects on the pulmonary condition,
adverse effects during hospitalization, and long-term neurodevelopmental sequelae assessed at 2 years corrected
gestational age. Analysis will be on an intention to treat basis.
Discussion: This trial will determine the efficacy and safety of postnatal hydrocortisone administration at a
moderately early postnatal onset compared to placebo for the reduction of the combined outcome mortality and
BPD at 36 weeks postmenstrual age in ventilator dependent preterm infants.
Trial registration number: Netherlands Trial Register (NTR): NTR2768
Background
Bronchopulmonary dysplasia (BPD) is the most com-
mon complication of premature birth, with a reported
incidence of 8% to 35% [1,2]. BPD is characterized by
chronic respiratory distress, the need for prolonged
respiratory support, an increased risk of recurrent pul-
monary infections leading to hospital readmissions
during the first years of life [3], and life-long alterations
in lung function [4-6]. BPD is also considered an impor-
tant risk factor for adverse neurodevelopmental outcome
after premature birth [7-11]. These long-term conse-
quences of BPD place a heavy burden on societal and
health care costs [12-15].
Pulmonary inflammation has been identified as an
important risk factor in the development of BPD, pro-
viding the rationale for treating patients at risk for BPD
with glucocorticoids, a group of drugs well known for
its strong anti-inflammatory effect [16-18]. Randomized
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controlled trials (RCTs) comparing dexamethasone to
placebo in ventilated preterm infants at risk for BPD
have shown that dexamethasone reduces the incidence
of the combined outcome death or BPD [19,20]. Dexa-
methasone seems to be most effective when initiated
between 7 to 14 days postnatal age, the so-called moder-
ately early treatment onset [21,22]. Unfortunately, more
recent follow-up studies seem to indicate that this bene-
ficial effect on the lung may be outweighed by an
increased risk of adverse neurodevelopmental outcome.
Despite the fact that this adverse effect on the newborn
brain has so far only been reported in studies investigat-
ing the early use of dexamethasone (i.e. initiated < 7
days of postnatal age), there is now a general concern
on its use in preterm infants [23-25]. Based on this con-
cern, the American Academy of Pediatrics, Canadian
Paediatric Society, and the European Association of
Perinatal Medicine have stated that the use of dexa-
methasone should be restricted to exceptional cases and
clinical trials should be performed to investigate the use
of alternative anti-inflammatory glucocorticoids, such as
hydrocortisone [26,27].
In response to this statement the use of dexamethasone
has dropped dramatically to approximately 10% of the
preterm infants at risk for BPD [28-30]. In addition, its
dose has been significantly reduced and administration is
often postponed until the 3rd or 4th week of life [23].
Some clinicians have started to use hydrocortisone, as
an alternative for dexamethasone. Animal studies have
suggested that, in contrast to dexamethasone, hydrocor-
tisone has no detrimental effect on the brain [31]. To
date, eight RCTs including 880 preterm infants investi-
gated a low hydrocortisone dose started within 72 hours
after birth (early treatment onset). Meta-analysis of
these trials failed to show a clear reduction in the inci-
dence of death or BPD [32]. Only one of these trials
reported long-term follow-up, showing no differences in
adverse neurodevelopmental sequelae [33].
To our knowledge, there are no placebo controlled ran-
domized trials that investigated the use of hydrocortisone
after the first week in life in ventilator dependent preterm
infants [34] The neonatal intensive care unit (NICU) at
the University Medical Center Utrecht has historically
used hydrocortisone after the first week of life for venti-
lated preterm infants at high risk for developing BPD. Ret-
rospective cohort studies conducted in this center seem to
indicate that hydrocortisone is effective in reducing BPD,
without causing serious long-term adverse effects [35-37].
However, these findings need to be confirmed or refuted
by a large randomized placebo controlled trial.
Aim of the study
To investigate if systemic hydrocortisone, started
between 7 - 14 days after birth, is safe and effective in
reducing the incidence of the combined outcome death
or BPD at 36 weeks PMA in chronically ventilated pre-
term infants, as compared to a placebo.
Study design
Multicenter randomized double-blind placebo-controlled
trial conducted in 15 NICUs in the Netherlands (n =
10) and Belgium (n = 5). The inclusion period will be 3
years, with a 2 year follow-up for each child.
Study population
Inclusion criteria
Preterm infants with:
- gestational age < 30 wks and/or birth weight <
1250 g
- ventilator dependency at 7-14 days PNA
- respiratory index (RI), defined as the product of
mean airway pressure (MAwP) and the fraction of
inspired oxygen (FiO2), of ≥ 3.5 for more than 12 h/day
for at least 48 hours, ensuring adequate oxygen satura-
tion (85-95%) and PaCO2 values (5.0-7.5 kPa).
Exclusion criteria
- chromosomal defects (e.g. trisomy 13, 18, 21)
- major congenital malformations that:
○ compromise lung function (e.g. surfactant protein
deficiencies, congenital diaphragmatic hernia)
○ result in chronic ventilation (e.g. Pierre Robin
sequence)
○ increase the risk of death or adverse neurodeve-
lopmental outcome (e.g. congenital cerebral
malformations)
- use of dexamethasone or hydrocortisone prior to
inclusion for the sole purpose of improving lung func-
tion and respiratory status
Sample size calculation
Estimating the a priori risk of death or BPD in preterm
infants less than 30 weeks gestation and ventilated in
the second week of life at 60 - 70% and defining an
absolute risk reduction of 15% or more (NNT = 7) as
clinically relevant, 175 patients need to be included in
each treatment arm (type I error of 5%, power of 80%).
Anticipating a 10% drop out of randomized patients, the
number of inclusions needs to be increased to 200
patients in each arm (total 400 patients).
Treatment of subjects
Trial medication and dosing
Trial medication will be prepared and distributed
according to Good Clinical Practice (GCP) and Good
Manufacturing Practice (GMP) guidelines. Using a dou-
ble-blinded treatment design, infants will be allocated to
either hydrocortisone or placebo treatment.
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The optimal (cumulative) dose of hydrocortisone is
currently unknown. Pharmacokinetic studies have not
been done, and are tedious in this field of developmen-
tal endocrinology. However, the NICU of the Univer-
sity Medical Center in Utrecht (the Netherlands) has
used a fixed hydrocortisone treatment regimen for sev-
eral decades, which has recently been adopted by 4
other Dutch NICUs. Retrospective cohort studies have
suggested that this treatment regimen is equally effec-
tive in reducing death or BPD compared with dexa-
methasone treated infants without causing an
increased risk of adverse neurological outcome [36,38].
Based on these findings and current clinical practice in
the Netherlands, we decided to adopt the dosing regi-
men from Utrecht for this study. Infants in the hydro-
cortisone group will be treated with hydrocortisone 5
mg/kg/day Q.I.D for 7 days, followed by 3.75 mg/kg/
day T.I.D. for 5 days, subsequently lowering the fre-
quency by one dose every 5 day. This leads to a total
duration of therapy of 22 days and a cumulative dose
of 72.5 mg/kg hydrocortisone. The infants in the con-
trol group receive a placebo treatment for the entire
22-day period in the same frequency as the hydrocorti-
sone group. Both hydrocortisone and placebo sche-
dules will be calculated according to weight on the day
of randomization and not adjusted to the actual weight
during the tapering schedule.
Treatment failure and use of open label hydrocortisone
In general, the use of open label hydrocortisone during
the 22 day treatment course is strongly discouraged.
Open label hydrocortisone use may be considered in
the following conditions:
1. The pulmonary condition is progressively deterior-
ating and the RI > 10 for more than 6 consecutive hours
2. The pulmonary condition of the patient is stable (RI
≤ 10) but not improving over time. If this is the case,
open label hydrocortisone may be considered if both of
the following conditions are met:
a. Extubation was attempted (extubation trial) within
24 hours before considering open label treatment
and this attempt failed
b. The patient has been on study medication for at
least 10 days
If, based on the aforementioned criteria, the physician
decides to start open label hydrocortisone, the study
medication is stopped and the patient will be recorded
as “treatment failure”. The open label hydrocortisone
dosage schedule is similar to that used in the study. In
case of treatment failure the following data will be col-
lected: timing of treatment failure, ventilator support
and settings, type of open label medication, starting
date, cumulative dose and duration of open label ther-
apy. These patients will be followed as all other patients.
Late rescue hydrocortisone therapy
If a patient is still on mechanical ventilation after com-
pletion of the study medication (i.e. day 22) and a subse-
quent extubation attempt failed, the physician may
consider treatment with late rescue hydrocortisone. The
late rescue hydrocortisone dosing schedule is similar to
that used in the study. Data on the starting date, cumu-
lative dose and duration of rescue therapy are collected.
The patients will be followed as all other patients.
Hydrocortisone for hypotension
In case of persistent hypotension, not (sufficiently)
responding to first line treatment with intravascular
volume expansion and inotropes (i.e. dopamine and/or
dobutamine) the use of hydrocortisone is allowed in a
dose of 3 mg/kg/day for 5 days [39]. The use of hydro-
cortisone for this indication will not be considered as
treatment failure. Data on timing, dose and duration
will be collected.
Inhalation corticosteroids
The use of inhaled corticosteroids in the first weeks of
life is strongly discouraged. However, its use is not an
exclusion criterion, because there is currently insuffi-
cient evidence that inhaled corticosteroids will reduce
the risk of death or BPD in preterm infants. Data on
timing, dose and duration will be collected.
Use of co-intervention
All randomized patients will be subjected to co-inter-
ventions, such as respiratory support and co-medication,
according to the guidelines and protocols of the indivi-
dual NICUs.
Methods/Design
Randomization
Eligible patients can be randomized between day 7 and
14 PNA. The first dose of study medication should be
administered within 24 hours after randomization. Ran-
domization will be centrally controlled and web-based
using a computer program designed for this study. This
trial will be protected from selection bias by using con-
cealed, stratified and blocked randomization. Randomi-
zation will be stratified per center and according to
gestational age stratum (stratum A: < 27 weeks; stratum
B: ≥ 27 weeks) and the allocation ratio will be 1:1 using
variable block sizes. Multiple birth infants will be rando-
mized independently, unless the parents or caregivers
explicitly request that the siblings are allocated to the
same treatment arm. In case of the latter the randomi-
zation software will be able to perform twin randomiza-
tion. The infants’ parents and all members of the
medical team, including investigators, remain blinded to
group assignment throughout the study.
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Withdrawal of individual subjects
Parents or caregivers may decide to withdraw their
infant from the study at any time and without any con-
sequences. Subjects withdrawn from the study will be
treated according to the standard of care, including neu-
rodevelopmental outcome assessment at the outpatient
clinic. To ensure adequate inclusion, withdrawn patients
will be replaced by additional inclusions.
Outcomes
Primary outcome
The primary outcome will be the dichotomous com-
bined outcome death or BPD at 36 weeks PMA. BPD at
36 weeks PMA will be assessed according to the
NICHD Consensus Statement using the classification of
severity as proposed by Jobe et.al. [18] and if indicated
the oxygen reduction test as described by Walsh et.al.
[18,40,41].
Secondary outcomes before hospital discharge
• treatment failure
• mortality at 28 days PNA, 36 weeks PMA and at
hospital discharge
• BPD at 28 days
• failure to extubate 3, 7, 14 and 21 days after initiat-
ing therapy
• duration of mechanical ventilation
• use of late rescue hydrocortisone treatment
• total time on supplemental oxygen
• length of hospital stay
• hypertension, as previously defined
• hyperglycemia requiring the use of insulin therapy
• nosocomial infection, including clinical or culture
proven sepsis, meningitis and pneumonia
• patent ductus arteriosus for which medical inter-
vention or surgical ligation is needed
• necrotising enterocolitis (NEC) with Bell stage II or
more
• gastrointestinal bleeding
• spontaneous intestinal perforation
• intraventricular haemorrhage (IVH) and/or peri-
ventricular leucomalacia (PVL), including grading on
cerebral ultrasonography according to protocol as
defined by Ment et.al. [42]
• retinopathy of prematurity, including grading
according to international classification [43]
• weight, head circumference and length at 36 weeks
PMA
Secondary outcomes after hospital discharge
• mortality
• number of readmissions since first discharge home
• weight, length and head circumference at 24
months corrected age (c.a.)
• Bayley Scales of Infant Development III, Mental
Developmental Index and Psychomotor Develop-
mental Index at 24 months c.a.
• cerebral palsy and severity of cerebral palsy using
gross motor function classification system at 24
months c.a.
• hearing loss requiring hearing aids at 24 months c.
a.
• blindness at 24 months c.a.
• behavioral problems (child behavior checklist) at
24 months c.a.
Data collection and statistical analysis
At the time of inclusion and randomization, baseline data
will be collected from all patients, including maternal
and patient characteristics, respiratory status and sup-
port, and the presence of serious morbidity as listed in
the secondary outcomes. During the 22 d treatment
course, respiratory support, blood gas analyses, serum
glucose levels, blood pressure and anthropometric data
will be collected on a daily bases. Outcome variables and
co-interventions will be recorded at 36 weeks PMA, hos-
pital discharge and at follow-up (2 years corrected age).
Data on eligible patients not included in the study will
also be recorded, including patient characteristics,
respiratory status and support, and the reason why the
patient was not included in the trial.
Data will be presented as mean ± standard deviations
or medians and (interquartile) ranges depending on
their distribution. Categorical data will be analyzed
using the Chi-square test. Continuous data will be ana-
lyzed using the Student’s t test or Mann-Whitney test as
appropriate. Both intention-to-treat and per-protocol
analysis will be employed since use of open label gluco-
corticoids may modulate possible treatment effects [44].
The effect of hydrocortisone on the primary outcome
BPD free survival will be assessed by multi-variable
logistic regression analysis including possible confoun-
ders. Statistical significance is set at p < 0.05.
Safety aspects and study monitoring
During the study all patients will be closely monitored
for adverse events. First, complications of preterm birth
and intensive care treatment, as listed in the outcome
section of this study protocol, will be reported once a
year to the Data Monitoring Committee (DMC) and the
Ethics Committee that approved the study protocol.
Second, all adverse events, not listed as outcomes in this
study will be reported within the appropriate time frame
to the Data Monitoring Committee (DMC) and the
Ethics Committee that approved the study protocol.
Finally, to enhance safety of this study the principle
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investigator and the study coordinator will be automati-
cally informed by email in case a patient
1) is treated with indomethacin or ibuprofen while
receiving study medication;
2) is diagnosed as having an intestinal perforation;
3) is diagnosed as having hypertension; and
4) receives open label hydrocortisone.
In addition to the above, the DMC will monitor efficacy
and safety outcomes and will provide the trial’s Steering
Committee with recommendations regarding continuing
or stopping the trial (for all patients or subgroups of
patients) when approximately 25% (safety only), 50%
(safety and efficacy) and 75% (safety and efficacy) of the
anticipated outcome data are available. The DMC will be
blinded to the treatment allocation, but may request the
data manager to reveal the allocation labels.
The study will be monitored by means of personal
visits to the investigators’ facilities and through other
communications (e.g., telephone calls, written corre-
spondence). The main goal of monitoring is to evaluate
the progress of the study, ensure the rights and well-
being of the subjects are protected, check that the
reported clinical study data are accurate, complete and
verifiable from source documents, and the conduct of
the study is in compliance with the approved protocol
and amendments, GCP and applicable national regula-
tory requirements. A monitoring visit will include a
review of the essential clinical study documents (regula-
tory documents, CRFs, source documents, drug disposi-
tion records, subject informed consent forms, etc.) as
well as discussion on the conduct of the study with the
investigator and staff.
In case of hypertension defined as a systolic blood
pressure > 80 mmHg for infants with a gestational age
of 24-26 wks, > 90 mmHg for infants 26-28 wks, and >
100 mmHg for infants ≥ 28 wks, the hydrocortisone
dose is lowered according to a predefined tampering
schedule. Data on the time, reason and dose adjustment
will be collected.
Ethical considerations
The study will be conducted according to the principles
of the Declaration of Helsinki [45] and in accordance
with the Medical Research Involving Human Subjects
Act (WMO). Patients can only be included in the study
after obtaining written informed consent from both par-
ents. Both parents will receive verbal and written infor-
mation on all aspects of the study, including possible
risks and benefits. The right of a parent to refuse parti-
cipation without a given reason will be respected. The
parents will remain free to withdraw their child at any
time from the study without consequences for further
treatment. The study protocol has been reviewed and
approved by the Ethics Committee of the Academic
Medical Center in Amsterdam (the Netherlands) and
the local Ethics Committee of each participating
hospital.
Handling and storage of data and documents
Data management will be implemented according to
GCP guidelines. Patient data will be entered via an elec-
tronic case record form (CRF) in a central GCP proof
web-based database to facilitate on-site data-entry.
Security is guaranteed with login names, login codes
and encrypted data transfer. The data of all subjects will
be coded and this coding will not be retraceable to the
individual patient. The key to this coding is safeguarded
by the investigator. Access will be granted to the princi-
pal investigator, local investigator, the study monitor,
quality assurance auditor, the Ethics Committee and the
inspector of the Ministry of Health. Data will be stored
for 15 years.
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